199 related articles for article (PubMed ID: 33466182)
1. The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis.
He X; Zhang T; Wu L; Wu Y; Zhou X
Medicine (Baltimore); 2021 Jan; 100(2):e24110. PubMed ID: 33466182
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer.
Zhou K; Zhou J; Zhang M; Liao W; Li Q
Clin Transl Oncol; 2020 Mar; 22(3):337-343. PubMed ID: 31041716
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine/tipiracil in the treatment of gastric cancer.
Fostea RM; Arkenau HT
Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil for the treatment of metastatic gastric cancer.
Kawazoe A; Shitara K
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125
[No Abstract] [Full Text] [Related]
9. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
10. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
[TBL] [Abstract][Full Text] [Related]
11. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
[TBL] [Abstract][Full Text] [Related]
14. Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
Giuliani J; Bonetti A
Eur J Cancer; 2020 Oct; 138():77-79. PubMed ID: 32871525
[No Abstract] [Full Text] [Related]
15. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
16. [Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Hamada S; Komatsu S; Shibata R; Konishi T; Matsubara D; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2056-2058. PubMed ID: 33468799
[TBL] [Abstract][Full Text] [Related]
17. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
Narita Y; Shoji H; Kawai S; Mizukami T; Nakamura M; Moriwaki T; Yamanaka T; Sunakawa Y; Kawakami H; Nishina T; Misumi T; Muro K
Future Oncol; 2021 Mar; 17(8):869-875. PubMed ID: 32954810
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
19. A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers.
Hamerton L; Gomes K; Fougeray R; Hook ES; Gomes MV; Hauch O; Bullement A
Future Oncol; 2023 Mar; 19(9):643-650. PubMed ID: 37115022
[No Abstract] [Full Text] [Related]
20. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
